Table 2 Comparison of PB lymphocyte apoptosis among jSLE patients based on the presence or absence of clinical and laboratory manifestations
Feature | Number of patients N = 100 (%) | Percentage of PB lymphocyte apoptosis, median (IQR) | P value* | |
|---|---|---|---|---|
Nephritis | present | 83 (83) | 15 (5.4) | 0.981 |
absent | 17 (17) | 10 (11.1) | ||
Antiphospholipid syndrome | present | 46 (46) | 9 (6.5) | 0.276 |
absent | 54 (54) | 6.2 (3.75) | ||
Arthritis | present | 72 (72) | 13.7 (10.9) | 0.357 |
absent | 28 (28) | 6.6 (2.7) | ||
Mucocutaneous | present | 28 (28) | 15 (18.4) | 0.648 |
absent | 72 (72) | 13.5 (5.8) | ||
Anti-ds DNA | present | 81 (81) | 13.9 (13) | 0.316 |
absent | 19 (19) | 8.4 (2.1) | ||
Leucopenia | present | 48 (48) | 19.6 (13.2) | 0.683 |
absent | 52 (52) | 8.7 (8.4) | ||
Hypocomplementenimia | present | 50 (50) | 10 (9.6) | 0.553 |
absent | 50 (50) | 4.6 (8) |